Insomnia Treatment Guidelines

First-Line Treatment: Cognitive Behavioral Therapy for Insomnia (CBT-I)

• The American Academy of Sleep Medicine recommends CBT-I as the initial treatment for all patients with chronic insomnia due to its superior long-term efficacy and favorable benefit-to-risk ratio compared to pharmacological options 1, 2
• CBT-I has been shown to be highly effective in the treatment of insomnia across all age groups with sustained benefits for up to 2 years 3
• Key components of effective CBT-I include sleep restriction therapy, stimulus control, sleep hygiene education, and cognitive restructuring to address maladaptive thoughts about sleep 1, 3

Pharmacological Options (Second-Line Only)

• The American Academy of Sleep Medicine suggests that medications should only be considered when patients are unable to participate in CBT-I, still have symptoms despite participation in CBT-I, or as a temporary adjunct to CBT-I 2
• Benzodiazepine receptor agonists (BzRAs) such as eszopiclone, zolpidem, zaleplon, triazolam, and temazepam may be considered for sleep onset and maintenance insomnia 4, 5
• Other approved medications include ramelteon for sleep onset insomnia and low-dose doxepin for sleep maintenance insomnia 4, 5

Sleep Hygiene Practices

• Sleep hygiene education alone is usually not adequate for treating severe chronic insomnia but should be included as part of a comprehensive treatment approach 3
• Important sleep hygiene practices include avoiding frequent daytime napping, spending too much time in bed, late evening exercise, caffeine, evening alcohol consumption, and smoking, as well as creating a comfortable sleep environment 3

Treatment Algorithm

• The initial approach should begin with CBT-I as the primary intervention 1, 2
• If CBT-I is ineffective or not feasible, consider short-term use of FDA-approved sleep medications with careful monitoring 2
• For older adults, use extra caution with medications due to increased risk of falls, cognitive impairment, and adverse effects 3

Important Considerations and Pitfalls

• Short-term use of medications is preferred due to concerns about tolerance, dependence, and adverse effects with long-term use 4
• Benzodiazepines and non-benzodiazepine hypnotics carry risks of falls, cognitive impairment, and dependence, particularly in older adults 1
• Regular follow-up is essential to monitor treatment response and address any emerging issues 1

Management of Insomnia with Cognitive Behavioral Therapy

Critical Considerations for Treatment

• The American Academy of Sleep Medicine, American College of Physicians, and VA/DoD recommend against using over-the-counter antihistamines or herbal supplements due to lack of efficacy data and safety concerns, especially daytime sedation and delirium in older patients, and avoiding long-term pharmacotherapy without periodic reassessment and concurrent behavioral interventions, as well as not using antipsychotics as first-line treatment due to problematic metabolic side effects 6
• Avoid long-term pharmacotherapy without periodic reassessment and concurrent behavioral interventions, and do not use antipsychotics as first-line treatment due to problematic metabolic side effects, according to the American Academy of Sleep Medicine 6

Management of Treatment-Refractory Insomnia

Medication Alternatives and Considerations

• The American Academy of Sleep Medicine recommends considering suvorexant 10-20 mg as an alternative orexin receptor antagonist with similar mechanism but different pharmacokinetics for patients who do not respond to Dayvigo 7, 8
• Ramelteon 8 mg, a melatonin receptor agonist, can be considered for sleep onset insomnia, with no abuse potential and safe for long-term use 7, 8
• Zaleplon 10 mg, an ultra-short-acting BzRA, can be used for sleep onset only and can be taken in the middle of the night if ≥4 hours remain before awakening 7, 8
• Low-dose doxepin 3-6 mg, a highly selective H1 antagonist, reduces wake after sleep onset by 22-23 minutes with strong evidence 7, 8
• Eszopiclone 2-3 mg, a BzRA, is effective for both sleep onset and maintenance and is approved for long-term use 7, 8
• The American Academy of Sleep Medicine explicitly recommends against using trazodone for insomnia treatment due to insufficient efficacy data 7, 8
• Benzodiazepines should be avoided due to higher risk of tolerance, dependence, cognitive impairment, and complex sleep behaviors compared to newer agents 9
• Over-the-counter antihistamines, such as diphenhydramine, should not be used due to lack of efficacy data, daytime sedation, anticholinergic effects, and delirium risk 7, 8
• Combining multiple sedatives should be avoided, as it significantly increases fall risk and cognitive impairment, and the American Academy of Sleep Medicine recommends undertreating with behavioral interventions instead of pharmacotherapy alone 10
• Pregabalin (Lyrica) interaction with Dayvigo should be considered, as both are CNS depressants, and combined use increases sedation risk 9

Guideline Recommendations for Managing Frequent Nighttime Awakenings in Adults

First‑Line Non‑Pharmacologic Treatment

• Cognitive Behavioral Therapy for Insomnia (CBT‑I) is the mandatory first‑line therapy for all adults with chronic insomnia, including frequent nighttime awakenings, and should be started before or together with any hypnotic medication. (American Academy of Sleep Medicine) 11

• CBT‑I provides superior long‑term efficacy compared with pharmacologic agents; therapeutic benefits are maintained for up to 2 years after treatment ends, whereas medication effects disappear when the drug is stopped. (moderate‑quality evidence) 12

• Stimulus‑control therapy: patients should reserve the bed for sleep only; if unable to return to sleep within ~20 minutes after awakening, they should get out of bed, engage in a relaxing activity until drowsy, then return to bed. (American Academy of Sleep Medicine) 11

• Sleep‑restriction therapy: limit time in bed to approximate actual sleep time + 30 minutes (minimum 5 hours) and adjust weekly based on sleep efficiency (total sleep time ÷ time in bed × 100 %). This consolidates sleep and reduces fragmentation. (American Academy of Sleep Medicine) 12

• Cognitive restructuring: identify and modify maladaptive beliefs such as “I must get 8 hours of sleep” or “My life will be ruined if I wake up at night.” (American Academy of Sleep Medicine) 11

• Relaxation techniques (e.g., progressive muscle relaxation, guided imagery, controlled breathing) are used to lower physiological arousal that perpetuates awakenings. (American Academy of Sleep Medicine) 11

• Sleep‑hygiene education (avoid caffeine ≥ 6 h before bedtime, eliminate evening alcohol, keep a consistent wake‑time, maintain a quiet‑cool bedroom, avoid screens ≥ 1 h before sleep) is insufficient as monotherapy and must be combined with the core CBT‑I components. (American Academy of Sleep Medicine) 12

CBT‑I Delivery Formats

• CBT‑I can be delivered via individual therapy, group sessions, telephone‑based programs, web‑based modules, or self‑help books; all formats demonstrate comparable efficacy. (American Academy of Sleep Medicine) 11

Pharmacologic Treatment (Second‑Line, After CBT‑I Initiation)

• Pharmacologic agents should be added only after CBT‑I has been initiated; they are intended to supplement—not replace—behavioral interventions. (American Academy of Sleep Medicine) 11

Medications Explicitly Not Recommended

• The American Academy of Sleep Medicine issues a weak recommendation against trazodone for insomnia because it yields only ~10 min reduction in sleep latency and ~8 min reduction in wake after sleep onset, provides no improvement in subjective sleep quality, and causes adverse events in ~75 % of older adults. (weak recommendation) 12

• Diphenhydramine and doxylamine (over‑the‑counter antihistamines) are not recommended due to lack of efficacy data, strong anticholinergic effects (confusion, urinary retention, falls, daytime sedation, delirium), and rapid tolerance development within 3–4 days. (American Academy of Sleep Medicine) 11

• Quetiapine and olanzapine (antipsychotics) must not be used for insomnia; evidence of benefit is weak and they carry significant risks including weight gain, metabolic syndrome, extrapyramidal symptoms, and increased mortality in elderly patients with dementia. (weak recommendation) 11

Implementation Pitfalls to Avoid

• Starting pharmacotherapy without first implementing CBT‑I violates strong guideline recommendations and results in less durable benefit. (American Academy of Sleep Medicine) 12

• Relying solely on sleep‑hygiene education without structured CBT‑I (stimulus‑control and sleep‑restriction) fails to produce durable improvement; the core behavioral components must be added. (American Academy of Sleep Medicine) 11